Cambridge Investment Research Advisors’s Standard BioTools LAB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-54,502	Closed	-$246K	–	3141
2021 Q1	$246K	Sell	54,502 -1,798	-3%	-$9.88K	﹤0.01%	2441
2020 Q4	$338K	Buy	56,300 +23,700	+73%	+$156K	﹤0.01%	2045
2020 Q3	$242K	Buy	32,600 +16,100	+98%	+$111K	﹤0.01%	2097
2020 Q2	$66K	Buy	+16,500	New	+$57.5K	﹤0.01%	2365
2019 Q4	–	Sell	-12,500	Closed	-$58K	–	2445
2019 Q3	$58K	Hold	12,500	–	–	﹤0.01%	2267
2019 Q2	$154K	Buy	+12,500	New	+$159K	﹤0.01%	2048

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cambridge Investment Research Advisors's LAB Position: Q2 2021 in Review

Cambridge Investment Research Advisors sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 54,502 shares — an estimated $246K sold.

Cambridge Investment Research Advisors first reported a position in LAB in Q2 2019 and held it in 6 quarters. The position peaked at $338K in Q4 2020. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

Cambridge Investment Research Advisors reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
Cambridge Investment Research Advisors sold 54,502 Standard BioTools shares in Q2 2021, an estimated $246K.
Cambridge Investment Research Advisors first reported a position in Standard BioTools in Q2 2019 and held it in 6 quarters.
Cambridge Investment Research Advisors's Standard BioTools position peaked at $338K in Q4 2020.
113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.